Tecan Reports Positive Growth in Q3 2025
The Tecan Group today shared an insightful update regarding its performance for the third quarter of 2025, revealing a mid-single-digit growth in local currencies. This follows a sequential improvement from previous quarters, where sales reflected a slight decline initially. In the Life Sciences Business segment, sales experienced a modest decline; however, the Partnering Business significantly bounced back with impressive growth.
Sales Performance and Trends
For the third quarter, Tecan's overall sales increased notably. The Partnering Business achieved growth in the low teens percentage range while the Life Sciences Business showed resilience. It's encouraging to see that in both segments, Tecan’s order intake surpassed sales for the quarter, indicating a strong demand and a positive future outlook. The book-to-bill ratio remains robust, signifying that customer interest is continuing to grow.
Looking Ahead: Full-Year 2025 Outlook
Tecan is optimistic about its sales outlook for the entirety of 2025. The company reaffirms its previous predictions while considering the evolving market conditions. They anticipate sales to be within the range of a low single-digit percentage decline to low single-digit percentage growth. Current trends suggest that full-year results may fall in the lower half of this range, reflecting cautious market expectations.
Segment Insights and Product Contributions
Sales to critical sectors such as US Academia and Government are nearing the midpoint of initially expected figures. In China, market demand shows signs of slowing down, affecting sales projections. On a positive note, newly launched products along with high-growth segments have begun making a significant impact, suggesting that innovation continues to drive sales despite other challenges.
Robust Financial Expectations
Besides sales, Tecan has reiterated its forecast for an adjusted EBITDA margin, projecting it to be between 17.5% to 18.5% of sales for 2025. This estimate is based on current exchange rates and excludes potential impacts from U.S. tariffs. They also calculated that elevated tariffs could yield about a hundred-basis-point decrease in the margin, underlining the importance of careful financial management during turbulent times.
Mid-Term Growth Projections
Looking forward, Tecan expresses confidence in its mid-term outlook. The company anticipates returning to standard organic growth rates within the mid- to high-single-digit percentage range. They aim to continuously enhance profitability, although expect market conditions to recover steadily rather than rapidly.
Company Positioning and Market Dynamics
Tecan is well-positioned to harness robust market trends driving demand for healthcare solutions globally. With a solid foundation built over years of expertise and innovation, Tecan is set to face the opportunities and challenges that lie ahead.
About Tecan
Tecan operates as a leader in laboratory automation, recognized for empowering healthcare innovations from life sciences to clinical environments. Founded in 1980 in Switzerland, the company continues to expand its global presence, with over 3,000 employees across several continents. In the financial year prior, Tecan reported significant sales, establishing itself firmly in the competitive landscape.
Contact Information
For further details about Tecan's operations or inquiries, please reach out to:
Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Frequently Asked Questions
What growth did Tecan report for Q3 2025?
Tecan reported a mid-single-digit growth in sales for the third quarter of 2025.
What is Tecan's sales outlook for the full year 2025?
The sales outlook for full-year 2025 is anticipated to range from a low single-digit percentage decline to low single-digit percentage growth.
How is Tecan's Partnering Business performing?
The Partnering Business has achieved strong sales growth, significantly improving in the low teens percentage range in local currencies.
What is Tecan's adjusted EBITDA margin forecast for 2025?
The adjusted EBITDA margin forecast is projected to be between 17.5% and 18.5% of sales.
How does Tecan intend to grow in the mid-term?
Tecan aims for a return to mid- to high-single-digit organic sales growth rates with enhanced profitability.
